Skip to content
TopicTracker
From HackerNewsView original
TranslationTranslation

Anthropic to develop its own (additional) drugs

Anthropic, the AI company behind the Claude model, announced plans to develop its own drugs, marking a significant expansion into AI-driven drug discovery and development.

Background

Anthropic is the AI company behind Claude, founded in 2021 by former OpenAI researchers. It has positioned itself as the "safety-first" AI lab, prioritizing alignment and responsible development. This article reports that Anthropic is moving beyond selling AI tools to biotech partners and will now develop its own drugs internally — a significant vertical integration play that puts it in direct competition with its own customers (pharma companies using Claude for R&D). The move signals that Anthropic sees drug discovery not just as an application for its AI, but as a potentially massive standalone business. It follows a broader trend of AI labs (like Google's DeepMind with AlphaFold) expanding into scientific discovery rather than just language models.

Related stories

  • The Wall Street Journal reported that Anthropic is approaching its first profitable quarter, with revenue expected to more than double to $10.9 billion in Q2, driven by explosive growth. The article examines the claim of operating profit (EBITDA) profitability.

  • President Trump has reportedly asked Anthropic, the AI safety company behind Claude, to undertake a task that may be technically or ethically impossible, raising questions about the future direction of AI regulation and corporate responsibility.